Dr. Suzanne Merrill

The data really over time has shown us that blue light is a technology that should be offered to our patients, that it has good enough evidence behind it, that it can impact our patients course of disease and outcome.

The data really over time has shown us that blue light is a technology that should be offered to our patients, that it has good enough evidence behind it, that it can impact our patients course of disease and outcome.

The data really over time has shown us that blue light is a technology that should be offered to our patients, that it has good enough evidence behind it, that it can impact our patients course of disease and outcome.

Even back in 2013, there was a meta-analysis of nine studies, which ultimately showed that detection of TA and T1 lesions may be up to 25% greater, okay, with blue light cystoscopy and use of CISFU. than compared to white light.

Even back in 2013, there was a meta-analysis of nine studies, which ultimately showed that detection of TA and T1 lesions may be up to 25% greater, okay, with blue light cystoscopy and use of CISFU. than compared to white light.

Even back in 2013, there was a meta-analysis of nine studies, which ultimately showed that detection of TA and T1 lesions may be up to 25% greater, okay, with blue light cystoscopy and use of CISFU. than compared to white light.

And overall, this translated looking at really the raw data from this meta-analysis that the rate of recurrence with use of blue light can be reduced by about 11%, and it can certainly prolong the time to recurrence by about seven-ish months.

And overall, this translated looking at really the raw data from this meta-analysis that the rate of recurrence with use of blue light can be reduced by about 11%, and it can certainly prolong the time to recurrence by about seven-ish months.

And overall, this translated looking at really the raw data from this meta-analysis that the rate of recurrence with use of blue light can be reduced by about 11%, and it can certainly prolong the time to recurrence by about seven-ish months.

Yeah, of course. It's a lot more surprising when we're talking to our patients about how common bladder cancer is. So in 2024, it ranks as the fourth most common cancer in men and the sixth most common cancer in the U.S. for both men and women. And so superficial bladder cancer actually comprises of greater than 60% of all our new diagnoses that go on.

Yeah, of course. It's a lot more surprising when we're talking to our patients about how common bladder cancer is. So in 2024, it ranks as the fourth most common cancer in men and the sixth most common cancer in the U.S. for both men and women. And so superficial bladder cancer actually comprises of greater than 60% of all our new diagnoses that go on.

Yeah, of course. It's a lot more surprising when we're talking to our patients about how common bladder cancer is. So in 2024, it ranks as the fourth most common cancer in men and the sixth most common cancer in the U.S. for both men and women. And so superficial bladder cancer actually comprises of greater than 60% of all our new diagnoses that go on.

And when people get superficial bladder cancer, the main concern is that there is a high risk of recurrence. And that recurrence in just year one can be as high as 60 percent and obviously escalates going forward in time. So this discussion we're going to have today about diagnosing it, getting the right stage and grade done,

And when people get superficial bladder cancer, the main concern is that there is a high risk of recurrence. And that recurrence in just year one can be as high as 60 percent and obviously escalates going forward in time. So this discussion we're going to have today about diagnosing it, getting the right stage and grade done,

And when people get superficial bladder cancer, the main concern is that there is a high risk of recurrence. And that recurrence in just year one can be as high as 60 percent and obviously escalates going forward in time. So this discussion we're going to have today about diagnosing it, getting the right stage and grade done,

And fully taking care of it when we go in for that TURBT is absolutely critical for both our patients and getting them on the right track for treatment.

And fully taking care of it when we go in for that TURBT is absolutely critical for both our patients and getting them on the right track for treatment.

And fully taking care of it when we go in for that TURBT is absolutely critical for both our patients and getting them on the right track for treatment.

Yeah, of course. So really importantly with the risk stratification that our AUA outlines, which is low, intermediate, and high risk, and nowadays we're even talking about a very high risk group that some of us use to really specify patients that are in need of a more comprehensive talk about even entertaining invasive surgery such as cystectomy.

Yeah, of course. So really importantly with the risk stratification that our AUA outlines, which is low, intermediate, and high risk, and nowadays we're even talking about a very high risk group that some of us use to really specify patients that are in need of a more comprehensive talk about even entertaining invasive surgery such as cystectomy.